How much revenue does Gencurix make?

Gencurix reported 7.55 billion KRW in revenue for fiscal year 2025, up 47.0% from 5.13 billion KRW in fiscal year 2024.

Where does Gencurix make most of its revenue?

South Korea: 96% of revenue by region in fiscal year 2023, followed by Overseas (4%).

What companies are similar to Gencurix?

Listed companies of a similar size in the same industry (DNA testing equipment) include Seegene, Inc. (096530.KQ), Genomictree Inc. (228760.KQ), Genesystem Co., Ltd. (363250.KQ), GeneMatrix Inc. (109820.KQ).

Gencurix Inc. (229000.KQ) Stock

About Gencurix Inc.

Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detectio...

At a glance

Gencurix reported revenue of 7.55 billion KRW for fiscal year 2025, up 47.0% from fiscal year 2024, and net income of -7.39 billion KRW. South Korea was its largest region in fiscal year 2023, with 96% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.